Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fujifilm Gets 10%-plus Stake in Australian Cell Therapy Startup
September 6, 2016
- Sato, Fuso to Copromote Emla Cream for Dialysis Patients
September 6, 2016
- Hisamitsu Starts PIII Trial of Transdermal Schizophrenia Treatment in US
September 6, 2016
- Celgene Seeks Japan Approval of Romidepsin for PTCL
September 6, 2016
- Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
September 6, 2016
- Sanofi’s PCSK9 Inhibitor Praluent Now Available in Japan
September 6, 2016
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Takeda to Develop Zika Vaccine with US Funding
September 5, 2016
- MSD Paid 15.2 Billion Yen to Doctors, Medical Institutions in 2015
September 5, 2016
- Oncolys to Evaluate Oncolytic Virus in Combination with Immune Checkpoint Inhibitors; Interim Results Expected in 2017
September 5, 2016
- Nippon Kayaku Seeks Add’l Dosage for Remicade Biosimilar in Psoriasis
September 2, 2016
- Takeda Kicks Off Global Observation Study for Multiple Myeloma
September 2, 2016
- Lilly, Osaka Univ. Join Forces on Obesity Research
September 2, 2016
- Chugai Transfers Marketing Authorization for Vesanoid to Fuji Pharma
September 2, 2016
- Sunovion to Acquire Canadian CNS Biotech: Sumitomo Dainippon
September 2, 2016
- Kipres/Singulair AG Hits Shelves in Japan: Kyorin Holdings
September 2, 2016
- Sandoz Taps Jason Hoffe as New Japan Head
September 2, 2016
- Otsuka, RIKEN Open Collaborative Research Center to Promote Regenerative Medicine
September 2, 2016
- Takecab Most Heavily Pitched Drug in July: Anterio
September 1, 2016
- Sovaldi Filed in Japan for All Hep C Genotypes Excluding Genotype 1: Gilead
September 1, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…